Alzheimer Disease
Conditions
Interventions
None listed
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - The participant must self-report unimpaired cognition. - The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
Exclusion criteria
Exclusion criteria: - Have seen a doctor about memory concerns. - Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition. - Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention. - Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Cognitive Worsening Within Cohorts as Measured by Cognitive Composite or Any of the Individual Composite Components [ Time Frame: Baseline up to 7 years Cognitive composite may consist of International Daily Symbol Substitution Test-Medicines (iDSSTm ), International Shopping List Test (ISLT), Continuous Paired Associate Learning Test (CPAL). Time to cognitive worsening is defined as a change in cognitive composite score or any of the individual composite components, from baseline at 2 consecutive visits. | — |
Countries
Japan, United States
Contacts
Public Contact- Trial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed